KeyBanc lowered the firm’s price target on ResMed (RMD) to $290 from $302 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The firm believes underlying MedTech trends continue to track well ahead of subdued market performance, which it thinks is mostly attributable to various macro items weighing on investor sentiment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed Steps Up PAP Innovation With New Amalfi vs. CLA11 Sleep Apnea Study
- ResMed: Buy Rating on Depressed Valuation as Market Overprices Philips and GLP‑1 Risks
- ResMed initiated with an Overweight at JPMorgan
- ResMed price target lowered to $255 from $300 at Evercore ISI
- ResMed price target lowered to $340 from $345 at Citi